RPS6KB1 and breast carcinoma: Our data are also in agreement with recent studies showing that inhibition of S6K1 with either PF4708671 (a selective inhibitor of S6K1) or specific siRNA led to a marked decrease of Mcl-1, enhancing tamoxifen- or glucose deprivation-induced apoptosis in breast cancer cell [33,46].